Cytotoxic action of low dose Ara-C. Investigations in a marrow grafted patient with relapse.
A 35-year-old woman relapsing from acute myeloid leukemia (AML) after a bone marrow transplantation (BMT) achieved complete remission by low dose Ara-C treatment. Phosphoglucomutase 1 (PGM 1) isoenzyme analysis gave evidence for complete chimerism before relapse, whereas relapsing leukemia was autochtonous. Low dose Ara-C treatment cleared the marrow of leukemic blasts and reestablished normal in vitro growth patterns of myelopoiesis. Disappearance of autochthonous cells and regrowth of transplanted hematopoiesis was shown by PGM 1 isoenzyme analysis. Thus, low dose Ara-C exerted its action--at least in this patient--by cytotoxic mechanisms.
Mittermüller
J
J
Kolb
H J
HJ
Gerhartz
H H
HH
Wilmanns
W
W
D000328:Adult; D001853:Bone Marrow / Q000187:drug effects / Q000201:enzymology; D016026:Bone Marrow Transplantation; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007527:Isoenzymes; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D010733:Phosphoglucomutase / Q000235:genetics
D007527:Isoenzymes; D003561:Cytarabine; D010733:Phosphoglucomutase